Evidence map›Paper›PMID 27722909›Full record

ArticleCancer immunology, immunotherapy : CII2016

Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.

Anning Li, Yue Wu, Jenny Linnoila, Benjamin Pulli, Cuihua Wang, Matthias Zeller, Muhammad Ali, Grant K Lewandrowski, Jinghui Li, Benoit Tricot and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Alginate lyase immobilizedActa pharmaceutica Sinica. B · 2025
    Article
  2. Article
  3. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Anning LiDepartment of Radiology, Huashan Hospital, Fudan University, 12 Urumchi Road, Shanghai, 200040, China.
Yue WuDepartment of Radiology, Huashan Hospital, Fudan University, 12 Urumchi Road, Shanghai, 200040, China.
Jenny LinnoilaCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Benjamin PulliCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Cuihua WangCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Matthias ZellerCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Muhammad AliCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Grant K LewandrowskiMolecular Neurogenetics Unit, Neuroscience Center, 149 13th St., Charlestown, MA, 02129, USA.
Jinghui LiCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Benoit TricotCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Edmund KeliherCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Gregory R WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Giulia FulciBrain Tumor Research Center, Simches Research Building, Neurosurgery Service, Massachusetts General Hospital, Boston, MA, 02114, USA.
Xiaoyuan FengDepartment of Radiology, Huashan Hospital, Fudan University, 12 Urumchi Road, Shanghai, 200040, China.
Bakhos A TannousMolecular Neurogenetics Unit, Neuroscience Center, 149 13th St., Charlestown, MA, 02129, USA.
Zhenwei YaoDepartment of Radiology, Huashan Hospital, Fudan University, 12 Urumchi Road, Shanghai, 200040, China. aocnhnr@126.com.
John W ChenCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA. jwchen@mgh.harvard.edu.
Harvard University · USCenter for Systems Biology · USMassachusetts General Hospital · USCenter for Neuro-Oncology · USFudan University · CNHuashan Hospital · CN

Funding

Interdepartmental Neuroscience CenterP30NS045776 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BREAKEFIELD, XANDRA OWENS, TANNOUS, BAKHOS A · 2003 to 2018
$11.1M
Myeloperoxidase, imaging biomarker and treatment target for multiple sclerosisR01NS070835 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JOHN W · 2010 to 2014
$1.9M
Imaging and Treating Inflammation in Stroke by Targeting MyeloperoxidaseR01NS072167 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JOHN W · 2010 to 2014
$1.8M
NINDS NIH HHS P30 NS045776NINDS NIH HHS R01 NS070835NINDS NIH HHS R01 NS072167
6 · The paper itself

Abstract

Currently, there is no stable and flexible method to label and track cytotoxic T lymphocytes (CTLs) in vivo in CTL immunotherapy. We aimed to evaluate whether the sulfo-hydroxysuccinimide (NHS)-biotin-streptavidin (SA) platform could chemically modify the cell surface of CTLs for in vivo tracking. CD8+ T lymphocytes were labeled with sulfo-NHS-biotin under different conditions and then incubated with SA-Alexa647. Labeling efficiency was proportional to sulfo-NHS-biotin concentration. CD8+ T lymphocytes could be labeled with higher efficiency with sulfo-NHS-biotin in DPBS than in RPMI (P < 0.05). Incubation temperature was not a key factor. CTLs maintained sufficient labeling for at least 72 h (P < 0.05), without altering cell viability. After co-culturing labeled CTLs with mouse glioma stem cells (GSCs) engineered to present biotin on their surface, targeting CTLs could specifically target biotin-presenting GSCs and inhibited cell proliferation (P < 0.01) and tumor spheres formation. In a biotin-presenting GSC brain tumor model, targeting CTLs could be detected in biotin-presenting gliomas in mouse brains but not in the non-tumor-bearing contralateral hemispheres (P < 0.05). In vivo fluorescent molecular tomography imaging in a subcutaneous U87 mouse model confirmed that targeting CTLs homed in on the biotin-presenting U87 tumors but not the control U87 tumors. PET imaging with

Indexed as

AnimalsBiotinylationDisease Models, AnimalFemaleHumansImmunotherapyMiceT-Lymphocytes, CytotoxicBiotinCytotoxic T lymphocytesImmunotherapyTumor

Identifiers

PMID27722909
PMCPMC5101144
OpenAlexW2528848155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.